Li Wan , Tianyun Ma , Boye Li , Xiaoming Shi , Shuwen Chen , Xiaoli Sun , Haotian Ge , Chuqiao Lu , Weiyong Yu , Ning Zhou , Yue Xu , Li Ma , Zhaoxia Wang
{"title":"Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma","authors":"Li Wan , Tianyun Ma , Boye Li , Xiaoming Shi , Shuwen Chen , Xiaoli Sun , Haotian Ge , Chuqiao Lu , Weiyong Yu , Ning Zhou , Yue Xu , Li Ma , Zhaoxia Wang","doi":"10.1016/j.intimp.2025.115161","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Hypoxia, as one of the hallmarks in the progression of solid tumors, has been established as critically important for tumor adaptive survival; however, its role in mediating tumor microenvironment remodeling in advanced lung adenocarcinoma (LUAD) remains incompletely defined.</div></div><div><h3>Methods</h3><div>Bioinformatics methods were conducted to establish a “hypoxia gene module” and perform molecular subtyping of advanced LUAD patients.Western blotting and immunohistochemistry analyses were performed to elucidate the role of PLAU-PLAUR (also known as uPA-uPAR) signaling activation in hypoxia-associated “Collagenic” LUAD development. Primary pulmonary fibroblasts were isolated, and a co-culture system was established for further investigation. QRT-PCR, Western blotting, and ELISA assays were employed to assess PLAU-PLAUR pathway involvement in CAFs activation. Additionally, CUT&RUN, mass spectrometry, immunofluorescence, and co-immunoprecipitation experiments were conducted to explore the molecular mechanisms of HIF1A-induced PLAU upregulation. In vivo studies were undertaken to examine PLAU-PLAUR activation's impact on the formation of a collagen-rich tumor microenvironment.</div></div><div><h3>Results</h3><div>We observed that advanced LUAD patients with high hypoxia exhibited higher fibrosis and increased infiltration of immunosuppressive cells in their microenvironment. Screening intercellular communication signals revealed abnormal activation of the PLAU-PLAUR pathway between tumor cells and fibroblasts in hypoxia-induced “Collagenic” LUAD. In vitro experiments confirmed that hypoxia upregulates PLAU in tumor cells, promoting CAFs activation. Furthermore, hypoxia-inducible factor 1α(HIF1A) recruits the mitophagy protein NIX for a non-canonical role: under hypoxia, NIX translocates to the nucleus, interacts with the PLAU transcription factor YY1, and enhances its binding to the PLAU promoter. We also identified that PLAU activates Hippo-YAP signaling upon binding to PLAUR on lung fibroblasts. In vitro studies demonstrated that Upamostat significantly attenuated fibroblast activation at tumor borders, enhanced CD8<sup>+</sup>T cell infiltration, and shifted macrophages from immunosuppressive to immunogenic states.</div></div><div><h3>Conclusions</h3><div>Activation of the PLAU-PLAUR pathway is essential for the progression of hypoxia-associated LUAD exhibiting a collagenous phenotype. Blocking the pathway provides a new research perspective for the development of immunotherapy for LUAD.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"162 ","pages":"Article 115161"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925011518","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Hypoxia, as one of the hallmarks in the progression of solid tumors, has been established as critically important for tumor adaptive survival; however, its role in mediating tumor microenvironment remodeling in advanced lung adenocarcinoma (LUAD) remains incompletely defined.
Methods
Bioinformatics methods were conducted to establish a “hypoxia gene module” and perform molecular subtyping of advanced LUAD patients.Western blotting and immunohistochemistry analyses were performed to elucidate the role of PLAU-PLAUR (also known as uPA-uPAR) signaling activation in hypoxia-associated “Collagenic” LUAD development. Primary pulmonary fibroblasts were isolated, and a co-culture system was established for further investigation. QRT-PCR, Western blotting, and ELISA assays were employed to assess PLAU-PLAUR pathway involvement in CAFs activation. Additionally, CUT&RUN, mass spectrometry, immunofluorescence, and co-immunoprecipitation experiments were conducted to explore the molecular mechanisms of HIF1A-induced PLAU upregulation. In vivo studies were undertaken to examine PLAU-PLAUR activation's impact on the formation of a collagen-rich tumor microenvironment.
Results
We observed that advanced LUAD patients with high hypoxia exhibited higher fibrosis and increased infiltration of immunosuppressive cells in their microenvironment. Screening intercellular communication signals revealed abnormal activation of the PLAU-PLAUR pathway between tumor cells and fibroblasts in hypoxia-induced “Collagenic” LUAD. In vitro experiments confirmed that hypoxia upregulates PLAU in tumor cells, promoting CAFs activation. Furthermore, hypoxia-inducible factor 1α(HIF1A) recruits the mitophagy protein NIX for a non-canonical role: under hypoxia, NIX translocates to the nucleus, interacts with the PLAU transcription factor YY1, and enhances its binding to the PLAU promoter. We also identified that PLAU activates Hippo-YAP signaling upon binding to PLAUR on lung fibroblasts. In vitro studies demonstrated that Upamostat significantly attenuated fibroblast activation at tumor borders, enhanced CD8+T cell infiltration, and shifted macrophages from immunosuppressive to immunogenic states.
Conclusions
Activation of the PLAU-PLAUR pathway is essential for the progression of hypoxia-associated LUAD exhibiting a collagenous phenotype. Blocking the pathway provides a new research perspective for the development of immunotherapy for LUAD.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.